Primary Tumor Location in MCC Has Prognostic Significance
The prognostic utility of tumor location in Merkel cell carcinoma (MCC) is assessed.
The prognostic utility of tumor location in Merkel cell carcinoma (MCC) is assessed.
Risk of stage-specific Merkel cell carcinoma (MCC) recurrence and mortality over time since diagnosis is estimated.
Factors associated with delays in treatment for patients with Merkel cell carcinoma were investigated.
The frequent and durable responses to PD-1/PD-L1–blocking antibodies confirm the importance of immune mechanisms in nonmelanoma skin cancer pathogenesis.
Although there are a number of treatments for Merkel cell carcinoma, none offers impressive results. Research directed toward finding predictive markers for response, and adjuvant therapies, are warranted.
For patients with advanced Merkel cell carcinoma (aMCC), pembrolizumab is associated with durable tumor control and favorable overall survival.
The Food and Drug Administration has granted accelerated approval to Keytruda (pembrolizumab; Merck) for the treatment of patients with recurrent locally advanced or metastatic Merkel cell carcinoma.
Merkel cell carcinoma is a rare form of skin cancer associated with higher mortality rates than other skin cancers.
Investigators report a rare case of combined Merkel cell and squamous cell carcinoma confined almost exclusively to the epidermis.
Approval of avelumab for the treatment of patients 12 years and older with Merkel cell carcinoma was granted by the FDA.